Search - tctmd.com

Displaying 1 - 20 of 125

Sort: Relevancy | Date

News Conference News ACC 2026

Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD

L.A. McKeown

April 02, 2026

News Conference News ACC 2026

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate

Todd Neale

April 02, 2026

News Conference News ACC 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Yael L. Maxwell

April 01, 2026

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

News Conference News ACC 2026

Clinician EHR Alerts Lead to Speedier Evaluation, Treatment of Valve Disease

Todd Neale

April 01, 2026

News Conference News ACC 2026

SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too

Caitlin E. Cox

March 30, 2026

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

News Conference News ACC 2026

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

Caitlin E. Cox

March 28, 2026

Presentation ACC 2026

Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease: The Ez-PAVE randomized clinical trial

Presenter: Byeong-Keuk Kim

March 28, 2026

News Conference News ACC 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

Michael O'Riordan

April 04, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Caitlin E. Cox

April 15, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Advertisement

Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Clinician EHR Alerts Lead to Speedier Evaluation, Treatment of Valve Disease

SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease: The Ez-PAVE randomized clinical trial

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

What’s Going to Be Hot at ACC 2025?

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content